Neuland Q2FY26 Total income at Rs.516.1 crore; EBITDA at Rs.156.9 crore

Neuland Laboratories Limited (NLL) (NSE: NEULANDLAB; BSE:524558), a pharmaceutical manufacturer providing active pharmaceutical ingredients (APIs), complex intermediates and custom manufacturing solutions services to customers located in around 80 countries, today announced financial results for the half year ended Sep 30th, 2025.

Commenting on the performance Mr. Sucheth Davuluri, Vice-Chairman and Chief Executive Officer of the Company said, "The record high revenue this quarter driven by CMS commercial projects led to the operating leverage reflected in the EBITDA margins, and we expect this momentum to continue through the rest of the year. Given the investments we are making Neuland is well positioned to take advantage of the number of growth opportunities available to us in both the CDMO as well as the generic APIs space."

In addition, Mr. Saharsh Davuluri, Vice Chairman and Managing Director, Neuland Laboratories added "Customer interest in Neuland's capabilities continues to be on the rise as we see increased engagement with a diverse range of customers. Our reputation and track record as an agile partner is enabling not just new business but for greater share of business from existing customers. Our investments are going according to plan and helping to further differentiate Neuland as a partner of choice."

Shares of Neuland Laboratories Limited was last trading in BSE at Rs. 17821.50 as compared to the previous close of Rs. 17552.85. The total number of shares traded during the day was 5147 in over 1929 trades.

The stock hit an intraday high of Rs. 18081.25 and intraday low of 17383.95. The net turnover during the day was Rs. 91685223.00.

Source : Equity Bulls

Keywords

NeulandLaboratories INE794A01010 Pharmaceuticals Q2FY26 H1FY26 ResultUpdate